Martin Holst Lange
Chief Scientific Officer at Novo Nordisk, leading scientific development for the company's obesity and metabolic disease therapeutics, including work on the CagriSema program and broader obesity pipeline.
Best podcasts with Martin Holst Lange
Ranked by the Snipd community
Feb 23, 2026 • 6min
Novo's Martin Holst Lange Talks New Weight Loss Shot
Martin Holst Lange, Chief Scientific Officer at Novo Nordisk, leads scientific development for obesity and metabolic therapies. He discusses why recent CagriSema trial results need context and how titration and higher-dose studies may change outcomes. He also outlines Novo Nordisk’s broader pipeline strategy and why the company chose a different scientific route than some competitors.
